Cell culture modeling to test therapies against hyperglycemia-mediated oxidative stress and injury

Antioxidants and Redox Signaling

Volumn 7, Issue 11-12, 2005, Pages 1494-1506

  Vincent, Andrea M ^a   Stevens, Martin J ^a   Backus, Carey ^a   Mclean, Lisa L ^a   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIOXIDANT; FREE RADICAL; NICOTINAMIDE; REACTIVE OXYGEN METABOLITE; THIOCTIC ACID;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; FLUOROMETRY; HIGH THROUGHPUT SCREENING; HYPERGLYCEMIA; INJURY; INSULIN DEPENDENT DIABETES MELLITUS; MODEL; NERVE CELL CULTURE; NERVE INJURY; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPINAL GANGLION;

ANIMALS; ANTIOXIDANTS; CELL CULTURE TECHNIQUES; CELL DEATH; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; GANGLIA, SPINAL; GLUCOSE; HYDROGEN PEROXIDE; HYPERGLYCEMIA; LIPID PEROXIDATION; MODELS, BIOLOGICAL; NEURONS; NIACINAMIDE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; THIOCTIC ACID;

ANIMALIA;

EID: 28844481889     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2005.7.1494     Document Type: Article

References (93)

1. Akizuki S, Yoshida S, Chambers DE, Eddy LJ, Parmley LF, Yellon DM, and Downey JM. Infarct size limitation by the xanthine oxidase inhibitor, allopurinol, in closed-chest dogs with small infarcts. Cardiovasc Res 19: 686-692, 1985.
2. Althaus FR, Kleczkowska HE, Malanga M, Muntener CR, Pleschke JM, Ebner M, and Auer B. Poly ADP-ribosylation: a DNA break signal mechanism. Mol Cell Biochem 193: 5-11, 1999.
3. Arnold WL, DeWall RA, Kezdi P, and Zwart HH. The effect of allopurinol on the degree of early myocardial ischemia. Am Heart J 99: 614-624, 1980.
4. Aruoma OI, Halliwell B, Hoey BM, and Butler J. The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem J 256: 251-255, 1988.
5. Berman RS and Martin W. Arterial endothelial barrier dysfunction: actions of homocysteine and the hypoxanthine-xanthine oxidase free radical generating system. Br J Pharmacol 108: 920-926, 1993.
6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
7. Burkart V, Wang ZQ, Radons J, Heller B, Herceg Z, Stingl L, Wagner EF, and Kolb H. Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. Nat Med 5: 314-319, 1999.
8. Butler R, Morris AD, Belch JJ, Hill A, and Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35: 746-751, 2000.
9. Cameron NE, Cotter MA, Horrobin DH, and Tritschler HJ. Effects of alpha-lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids. Diabetologia 41: 390-399, 1998.
10. Cameron NE, Eaton SE, Cotter MA, and Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44: 1973-1988, 2001.
11. Castelli P, Condemi AM, Brambillasca C, Fundaro P, Botta M, Lemma M, Vanelli P, Santoli C, Gatti S, and Riva E. Improvement of cardiac function by allopurinol in patients undergoing cardiac surgery. J Cardiovasc Pharmacol 25: 119-125, 1995.
12. Chambers DJ, Braimbridge MV, and Hearse DJ. Free radicals and cardioplegia: allopurinol and oxypurinol reduce myocardial injury following ischemic arrest. Ann Thorac Surg 44: 291-297, 1987.
13. Chase HP, Butler-Simon N, Garg S, McDuffie M, Hoops SL, and O'Brien D. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 33: 444-446, 1990.
14. Chatterjee PK, Zacharowski K, Cuzzocrea S, Otto M, and Thiemermann C. Inhibitors of poly (ADP-ribose) synthetase reduce renal ischemia-reperfusion injury in the anesthetized rat in vivo. FASEB J 14: 641-651, 2000.
15. Cheng C and Zochodne DW. Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes 52: 2363-2371, 2003.
16. Clancy RR, McGaurn SA, Goin JE, Hirtz DG, Norwood WI, Gaynor JW, Jacobs ML, Wernovsky G, Mahle WT, Murphy JD, Nicolson SC, Steven JM, and Spray TL. Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest. Pediatrics 108: 61-70, 2001.
17. Coghlan JG, Flitter WD, Clutton SM, Panda R, Daly R, Wright G, Ilsley CD, and Slater TF. Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 107: 248-256, 1994.
18. Delaney CL, Russell JW, Cheng H-L, and Feldman EL. Insulin-like growth factor-I and over-expression of Bcl-xL prevent glucose-mediated apoptosis in Schwann cells. J Neuropathol Exp Neurol 60: 147-160, 2001.
19. Elliott RB and Chase HP. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 34: 362-365, 1991.
20. Elliott RB, Pilcher CC, Fergusson DM, and Stewart AW. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab 9: 501-509, 1996.
21. Feldman EL. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J Clin Invest 111: 431-433, 2003.
22. Feldman EL, Stevens MJ, Russell JW, and Greene DA. Diabetic neuropathy. In: Principles and Practice of Endocrinology and Metabolism, edited by Becker KL. Philadelphia: Lippincott Williams & Wilkins, 2001, pp. 1391-1399.
23. Feldman EL, Stevens MJ, Russell JW, and Greene DA. Somatosensory neuropathy. In: Ellenberg and Rifkin's Diabetes Mellitus, edited by Porte D Jr, Sherwin RS, and Baron A. New York: McGraw-Hill, 2002, pp. 771-788.
24. Friedl HP, Smith DJ, Till GO, Thomson PD, Louis DS, and Ward PA. Ischemia-reperfusion in humans. Appearance of xanthine oxidase activity. Am J Pathol 136: 491-495, 1990.
25. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, and Levison SW. Diabetic retinopathy. More than meets the eye. Surv Ophthalmol 47 Suppl 2: S253-S262, 2002.
26. Garrett NE, Malcangio M, Dewhurst M, and Tomlinson DR. α-Lipoic acid corrects neuropeptide deficits in diabetic rats via induction of trophic support. Neurosci Lett 222: 191-194, 1997.
27. Gil J, Almeida S, Oliveira CR, and Rego AC. Cytosolic and mitochondrial ROS in staurosporine-induced retinal cell apoptosis. Free Radic Biol Med 35: 1500-1514, 2003.
28. Gimpel JA, Lahpor JR, van der Molen AJ, Damen J, and Hitchcock JF. Reduction of reperfusion injury of human myocardium by allopurinol: a clinical study. Free Radic Biol Med 19: 251-255, 1995.
29. Halliwell B. Oxidative stress in cell culture: an under-appreciated problem? FEBS Lett 540: 3-6, 2003.
30. Johnson WD, Kayser KL, Brenowitz JB, and Saedi SF. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J 121: 20-24, 1991.
31. Kishi M, Mitsui M, Nagamatsu M, Nickander KK, Schmelzer JD, Tanabe J, Yao JK, and Low PA. Dorsal root ganglion pathology in chronic experimental diabetic neuropathy. J Peripher Nerv Syst 6: 152-153, 2001.
32. Kishi M, Tanabe J, Schmelzer JD, and Low PA. Morphometry of dorsal root ganglion in chronic experimental diabetic neuropathy. Diabetes 51: 819-824, 2002.
33. Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, and Gale EA. Safety of high-dose nicotinamide: a review. Diabetologia 43: 1337-1345, 2000.
34. Kolb H and Burkart V. Nicotinamide in type 1 diabetes. Mechanism of action revisited. Diabetes Care 22 Suppl 2: B16-B20, 1999.
35. Kretowski A, Mysliwiec J, Szelachowska M, Kinalski M, and Kinalska I. Nicotinamide inhibits enhanced in vitro production of interleukin-12 and tumour necrosis factor-alpha in peripheral whole blood of people at high risk of developing type 1 diabetes and people with newly diagnosed type 1 diabetes. Diabetes Res Clin Pract 47: 81-86, 2000.
36. Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giani G, and Kolb H. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes 47: 980-984, 1998.
37. Lewis CM, Canafax DM, Sprafka JM, and Barbosa JJ. Double-blind randomized trial of nicotinamide on early-onset diabetes. Diabetes Care 15: 121-123, 1992.
38. Li YP and Lombardini JB. Taurine inhibits protein kinase C-catalyzed phosphorylation of specific proteins in a rat cortical P2 fraction. J Neurochem 56: 1747-1753, 1991.
39. Maitra I, Serbinova E, Trischler H, and Packer L. Alpha-lipoic acid prevents buthionine sulfoximine-induced cataract formation in newborn rats. Free Radic Biol Med 18: 823-829, 1995.
40. Mandrup-Poulsen T, Reimers JI, Andersen HU, Pociot F, Karlsen AE, Bjerre U, and Nerup J. Nicotinamide treatment in the prevention of insulin-dependent diabetes mellitus. Diabetes Metab Rev 9: 295-309, 1993.
41. Manna R, Migliore A, Martin LS, Ferrara E, Ponte E, Marietti G, Scuderi F, Cristiano G, Ghirlanda G, and Gambassi G. Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion. Br J Clin Pract 46: 177-179, 1992.
42. McCord JM, Roy RS, and Schaffer SW. Free radicals and myocardial ischemia. The role of xanthine oxidase. Adv Myocardiol 5: 183-189, 1985.
43. McDonald MC, Filipe HM, and Thiemermann C. Effects of inhibitors of the activity of poly (ADP-ribose) synthetase on the organ injury and dysfunction caused by haemorrhagic shock. Br J Pharmacol 128: 1339-1345, 1999.
44. McLaughlin B, Pal S, Tran MP, Parsons AA, Barone FC, Erhardt JA, and Aizenman E. p38 activation is required upstream of potassium current enhancement and caspase cleavage in thiol oxidant-induced neuronal apoptosis. J Neurosci 21: 3303-3311, 2001.
45. Mendola G, Casamitjana R, and Gomis R. Effect of nicotinamide therapy upon B-cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia 32: 160-162, 1989.
46. Nagamatsu M, Nickander KK, Schmelzer JD, Raya A, Wittrock DA, Trischler H, and Low PA. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18: 1160-1167, 1995.
47. Nakamura J, Del Monte MA, Shewach D, Lattimer SA, and Greene DA. Inhibition of phosphatidylinositol synthase by glucose in human retinal pigment epithelial cells. Am J Physiol 262: E417-E426, 1992.
48. Nicholson DW, and Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 22: 299-306, 1997.
49. Obrosova IG, Fathallah L, and Greene DA. Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL-alpha-lipoic acid. Eur J Pharmacol 398: 139-146, 2000.
50. Obrosova IG, Fathallah L, and Stevens MJ. Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy. Exp Neural 172: 211-219, 2001.
51. Obrosova IG, Minchenko AG, Marinescu V, Fathallah L, Kennedy A, Stockert CM, Frank RN, and Stevens MJ. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 44: 1102-1110, 2001.
52. Obrosova IG, Stevens MJ, and Lang HJ. Diabetes-induced changes in retinal NAD-redox status: pharmacological modulation and implications for pathogenesis of diabetic retinopathy. Pharmacology 62: 172-180, 2001.
53. Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, and Stevens MJ. Al-dose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 52: 864-871, 2003.
54. Obrosova IG, Li F, Abatan OI, Forsell MA, Komjati K, Pacher P, Szabo C, and Stevens MJ. Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes 53: 711-720, 2004.
55. Pasantes-Morales H, Wright CE, and Gaull GE. Protective effect of taurine, zinc and tocopherol on retinol-induced damage in human lymphoblastoid cells. J Nutr 114: 2256-2261, 1984.
56. Pisarenko OI, Lakomkin VL, Studneva IM, Timoshin AA, Kuzmin Al, Ruuge EK, and Kapelko VI. Allopurinol-enhanced postischemic recovery in the isolated rat heart involves repletion of high-energy phosphates. Biochem Med Metab Biol 51: 16-26, 1994.
57. Pociot F, Reimers JI, and Andersen HU. Nicotinamide-biological actions and therapeutic potential in diabetes prevention. IDIG Workshop, Copenhagen, Denmark, 4-5 December 1992. Diabetologia 36: 574-576, 1993.
58. Pop-Busui R, Sullivan KA, Van Huysen C, Bayer L, Cao X, Towns R, and Stevens MJ. Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, and functional deficits. Exp Neural 168: 259-272, 2001.
59. Pop-Busui R, Marinescu V, Van Huysen C, Li F, Sullivan K, Greene DA, Larkin D, and Stevens MJ. Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. Diabetes 51: 2619-2628, 2002.
60. Pop-Busui R, Kirkwood I, Schmid H, Marinescu V, Schroeder J, Larkin D, Yamada E, Raffel DM, and Stevens MJ. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol 44: 2368-2374, 2004.
61. Pozzilli P, Visalli N, Ghirlanda G, Manna R. and Andreani D. Nicotinamide increases C-peptide secretion in patients with recent onset type 1 diabetes. Diabet Med 6: 568-572, 1989.
62. Pozzilli P, Visalli N, Signore A, Baroni MG, Buzzetti R, Cavallo MG, Boccuni ML, Fava D, Gragnoli C, Andreani D, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia 38: 848-852, 1995.
63. Rashid MA and William-Olsson G. Influence of allopurinol on cardiac complications in open heart operations. Ann Thorac Surg 52: 127-130, 1991.
64. Russell JW, Sullivan KA, Windebank AJ, Herrmann DN, and Feldman EL. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis 6: 347-363, 1999.
65. Russell JW, Golovoy D, Vincent AM, Mahendru P, Olzmann JA, Mentzer A, and Feldman EL. High glucose induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J 16: 1738-1748, 2002.
66. Schmeichel AM, Schmelzer JD, and Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 52: 165-171, 2003.
67. Simbulan-Rosenthal CM, Rosenthal DS, Iyer S, Boulares AH, and Smulson ME. Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis. J Biol Chem 273: 13703-13712, 1998.
68. Simmons Z and Feldman EL. Treatment of diabetic neuropathy. In: The Evidence Base for Diabetes Care, edited by Williams R, Herman W, Kinmonth A-L, and Wareham NJ. West Sussex, U.K.: John Wiley & Sons, 2002, pp. 555-576.
69. Skyler JS. Microvascular complications. Retinopathy and nephropathy. Endocrinol Metab Clin North Am 30: 833-856, 2001.
70. Srinivasan S, Stevens MJ, and Wiley JW. Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes 49: 1932-1938, 2000.
71. Stevens MJ, Obrosova I, Cao X, Van Huysen C, and Greene DA. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49: 1006-1015, 2000.
72. Stevens MJ, Obrosova I, Pop-Busui R, Greene DA, and Feldman EL. Pathogenesis of diabetic neuropathy. In: Ellenberg and Rifkin's Diabetes Mellitus, edited by Porte D Jr, Sherwin RS, and Baron A. New York: McGraw-Hill, 2002, pp. 747-770.
73. Szabo C. Role of poly(ADP-ribose)synthetase in inflammation. Eur J Pharmacol 350: 1-19, 1998.
74. Tabayashi K, Suzuki Y, Nagamine S, Ito Y, Sekino Y, and Mohri H. A clinical trial of allopurinol (Zyloric) for myocardial protection. J Thorac Cardiovasc Surg 101: 713-718, 1991.
75. Thies RL and Autor AP. Reactive oxygen injury to cultured pulmonary artery endothelial cells: mediation by poly(ADP-ribose) polymerase activation causing NAD depletion and altered energy balance. Arch Biochem Biophys 286: 353-363, 1991.
76. Trachtman H, Futterweit S, and Bienkowski RS. Taurine prevents glucose-induced lipid peroxidation and increased collagen production in cultured rat mesangial cells. Biochem Biophys Res Commun 191: 759-765, 1993.
77. Vague P, Vialettes B, Lassmann-Vague V, and Vallo JJ. Nicotinamide may extend remission phase in insulin-dependent diabetes. Lancet 1: 619-620, 1987.
78. Vague P, Picq R, Bernal M, Lassmann-Vague V, and Vialettes B. Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients. Diabetologia 32: 316-321, 1989.
79. Van Bel F, Shadid M, Moison RM, Dorrepaal CA, Fontijn J, Monteiro L, Van De Bor M, and Berger HM. Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity. Pediatrics 101: 185-193, 1998.
80. Vincent AM, Russell JW, Low P, and Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 25: 612-628, 2003.
81. Vincent AM, Olzmann JA, Brownlee M, Sivitz WI, and Russell JW. Uncoupling proteins prevent glucose-induced neuronal oxidative stress and programmed cell death. Diabetes 53: 726-734, 2004.
82. Vincent AM, McLean LL, Backus C, and Feldman EL. Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J online: 10.109/fj.0425i3fje, 2005.
83. Vinik AI, Erbas T, Pfeifer MA, Feldman EL, Stevens MJ, and Russell JW. Diabetic autonomic neuropathy. In: Ellenberg and Rifkin's Diabetes Mellitus, edited by Porte D Jr, Sherwin RS, and Baron A. New York: McGraw-Hill, 2002, pp. 789-804.
84. Visalli N, Cavallo MG, Signore A, Baroni MG, Buzzetti R, Fioriti E, Mesturino C, Fiori R, Lucentini L, Matteoli MC, Crino A, Corbi S, Spera S, Teodonio C, Paci F, Amoretti R, Pisano L, Suraci C, Multari G, Sulli N, Cervoni M, De Mattia G, Faldetta MR, Boscherini B, Pozzilli P, et al. A multicentre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI). Diabetes Metab Res Rev 15: 181-185, 1999.
85. 31P NMR study in unanesthetized immature rats. Neurosci Lett 144: 103-106, 1992.
86. Windebank AJ and Feldman EL. Diabetes and the nervous system. In: Neurology and General Medicine, edited by Aminoff MJ. New York: Churchill Livingstone, 2001, pp. 341-364.
87. Zhao H, Kalivendi S, Zhang H, Joseph J, Nithipatikom K, Vasquez-Vivar J, and Kalyanaraman B. Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: potential implications in intracellular fluorescence detection of superoxide. Free Radic Biol Med 34: 1359-1368, 2003.
88. Zhu H, He M, Bannenberg GL, Moldeus P, and Shertzer HG. Effects of glutathione and pH on the oxidation of biomarkers of cellular oxidative stress. Arch Toxicol 70: 628-634, 1996.
89. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K, Gries FA, Ticinelli EC, Hahnzog B, Nehrdich D, Netten C, Dannehl K, Peukert M, Wessel K, Anders M, Bräuning H, Brun M, Brunner E, Von Bü ltzingslöwen S, Donaubauer B, Forchheim W, Funke K, Gerlach-Eniyew S, and Hampel T. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid: a 3-week multicentre randomized controlled trial (ALADIN study). Diabetologia 38: 1425-1433, 1995.
90. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, and Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 20: 369-373, 1997.
91. Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schutte K, Kerum G, and Malessa R. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 22: 1296-1301, 1999.
92. Zingarelli B, Szabo C, and Salzman AL. Blockade of poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis. Gastroenterology 116: 335-345, 1999.
93. Zweier JL, Broderick R, Kuppusamy P, Thompson-Gorman S, and Lutty GA. Determination of the mechanism of free radical generation in human aortic endothelial cells exposed to anoxia and reoxygenation. J Biol Chem 269: 24156-24162, 1994.